BioSpace News Archive

Sympazan® (clobazam) continues to meet key performance metrics and market penetration FDA Type A meeting for Libervant™ (diazepam) Buccal Film scheduled for November 12, 2020 Completed dosing in Phase 1 Pharmacokinetic (PK) trial for AQST-108 (epinephrine) Execution of monetization agreement providing up to $125 million for royalty rights in KYNMOBI™ (apomorphine HCI)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and financial results for the three and nine months ended September 30, 2020.

- Amgen (NASDAQ:AMGN) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference at 4:15 p.m. ET on Monday , Nov. 9, 2020, in Scottsdale, Ariz. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen and Peter H. Griffith , executive vice president and chief financial officer, wil

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting to be held online from December 5-8, 2020. The abstracts are available on the ASH website a

Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda ® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020. Jeff had previously been appointed as interim CEO in May 2020 while continuing to serve on the Board of Directors. “Jeff ha

Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing s arcoma Interim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing s arcoma demonstrated two complete responses , with no relapses after complete response Strengthened the balance sheet by securing $ 10.1 million in equity financing during Q3 2020

10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.com About 10x Genomics 10x Ge

Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that it has received authorization from FDA to proceed with a Phase 2 clinical trial under an Investigational New Drug (IND) application for its amniotic tissue-based product, PalinGen® Flow.

MorphoSys AG Prime Standard Segment; MDAX & TecDAX; announced that multiple abstracts regarding the company’s proprietary key asset tafasitamab have been accepted for poster presentations and online publication at the upcoming 62nd ASH Virtual Annual Meeting and Exposition from December 05-December 08, 2020.